Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- ctDNA in Neoadjuvant-Treated Breast Cancer Reflects Response and Survival
- Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation
- Taselisib or Placebo With Fulvestrant in ER-Positive, PIK3CA-Mutant, HER2-Negative Advanced Breast Cancer
- Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Extended Therapy for HR+ Early-Stage Breast Cancer Patients
- Paclitaxel–Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
- Efficacy of Neratinib in HER2-Positive, HR-Positive Early-Stage Breast Cancer
- Race Impacts Clinical Outcomes in HR-Positive, HER2-Negative, Node-Negative Breast Cancer
- Key Takeaways From ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer
- Tucatinib and HRQoL Among Patients With HER2+ Metastatic Breast Cancer
- Key Takeaways From ESMO: Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting